Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-09-29
DOI
10.3389/fimmu.2022.977265
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
- (2021) René Westhovens et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
- (2021) Bernard Combe et al. ANNALS OF THE RHEUMATIC DISEASES
- PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
- (2021) Juliana Setyawan et al. DRUG SAFETY
- The role for JAK Inhibitors in the Treatment of Immune-Mediated Rheumatic and related conditions
- (2021) George E. Fragoulis et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies
- (2021) Chang Xu et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2021) Liana Fraenkel et al. ARTHRITIS CARE & RESEARCH
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs
- (2020) Y. H. Lee et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
- Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis
- (2020) Young Ho Lee et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- (2020) Faping Wang et al. MAYO CLINIC PROCEEDINGS
- Venous Thromboembolism Risk With JAK Inhibitors: A Meta‐Analysis
- (2020) Mark Yates et al. Arthritis & Rheumatology
- Rheumatoid Arthritis
- (2019) Jeffrey A. Sparks ANNALS OF INTERNAL MEDICINE
- Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis
- (2019) Peter C. Taylor et al. Arthritis & Rheumatology
- Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
- (2019) Wenhui Xie et al. ANNALS OF THE RHEUMATIC DISEASES
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
- (2019) Katie Bechman et al. RHEUMATOLOGY
- Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Gerd R Burmester et al. LANCET
- Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
- (2018) Paul Emery et al. ADVANCES IN THERAPY
- Clinical significance of Janus Kinase inhibitor selectivity
- (2018) Ernest H Choy RHEUMATOLOGY
- A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate
- (2017) Roy Fleischmann EXPERT OPINION ON PHARMACOTHERAPY
- Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
- (2017) Edward C. Keystone et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- (2017) Roy Fleischmann et al. LANCET
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis
- (2016) Maria-Cecilia Vieira et al. CLINICAL THERAPEUTICS
- Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis
- (2015) Felicity Buckley et al. Journal of Managed Care & Specialty Pharmacy
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Back to the future: oral targeted therapy for RA and other autoimmune diseases
- (2013) John J. O'Shea et al. Nature Reviews Rheumatology
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now